![[ Back to EurekAlert! ]](http://www.eurekalert.org/images/back2e.gif){kind=small}
Public release date: 16-Feb-2012[ | E-mail |
Share ] Contact: Beth Bukata
bethb@astro.org
703-839-7332
American Society for Radiation Oncology
Stereotactic body radiotherapy (SBRT) provides better overall survival rates than surgery for lung cancer patients with severe chronic obstructive pulmonary disease (COPD), a disease commonly associated with lung cancer, according to a study in the upcoming March issue of the International Journal of Radiation, Oncology, Biology, Physics, the official scientific journal of the American Society for Radiation Oncology (ASTRO).
COPD is a blanket term for progressive lung diseases, including emphysema, chronic bronchitis and refractory asthma. It is characterized by increasing breathlessness and is present in 50 to 70 percent of lung cancer patients at the time of diagnosis. Patients with severe forms of this disease have a high annual mortality rate, even when they do not have lung cancer.
Surgery has been the standard treatment for Stage I non-small-cell lung cancer patients, but when the patient has COPD their chances of postoperative complications increase. SBRT, a newer radiation treatment, has been proven to be safe and effective in Stage I lung cancer patients who are not good surgical candidates.
Researchers looked at outcomes of post-SBRT Stage I lung cancer patients with severe COPD. The mean 30-day mortality rate post-SBRT was zero compared to 10 percent post-surgery. The overall survival rate post-SBRT was 79-95 percent at one year and 43-70 percent at three years. Post-surgery overall survival rates at one and three years were 45-86 percent and 31-66 percent, respectively.
"SBRT is a safe and effective less-invasive option for lung cancer patients with COPD that does not have the added risks of surgery-related mortality and prolonged hospitalization," David Palma, MD, MSc, lead author of the study and a radiation oncologist at the London Regional Cancer Program in London, Ontario, Canada, said. "All eligible patients should be evaluated in a multidisciplinary setting and afforded an informed decision of the risks and benefits of both surgery and SBRT."
###
ASTRO is the largest radiation oncology society in the world, with more than 10,000 members who specialize in treating patients with radiation therapies. As the leading organization in radiation oncology, biology and physics, the Society is dedicated to improving patient care through education, clinical practice, advancement of science and advocacy. For more information on radiation therapy, visit http://www.rtanswers.org. To learn more about ASTRO, visit http://www.astro.org.
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Public release date: 16-Feb-2012[ | E-mail |
Share ] Contact: Beth Bukata
bethb@astro.org
703-839-7332
American Society for Radiation Oncology
Stereotactic body radiotherapy (SBRT) provides better overall survival rates than surgery for lung cancer patients with severe chronic obstructive pulmonary disease (COPD), a disease commonly associated with lung cancer, according to a study in the upcoming March issue of the International Journal of Radiation, Oncology, Biology, Physics, the official scientific journal of the American Society for Radiation Oncology (ASTRO).
COPD is a blanket term for progressive lung diseases, including emphysema, chronic bronchitis and refractory asthma. It is characterized by increasing breathlessness and is present in 50 to 70 percent of lung cancer patients at the time of diagnosis. Patients with severe forms of this disease have a high annual mortality rate, even when they do not have lung cancer.
Surgery has been the standard treatment for Stage I non-small-cell lung cancer patients, but when the patient has COPD their chances of postoperative complications increase. SBRT, a newer radiation treatment, has been proven to be safe and effective in Stage I lung cancer patients who are not good surgical candidates.
Researchers looked at outcomes of post-SBRT Stage I lung cancer patients with severe COPD. The mean 30-day mortality rate post-SBRT was zero compared to 10 percent post-surgery. The overall survival rate post-SBRT was 79-95 percent at one year and 43-70 percent at three years. Post-surgery overall survival rates at one and three years were 45-86 percent and 31-66 percent, respectively.
"SBRT is a safe and effective less-invasive option for lung cancer patients with COPD that does not have the added risks of surgery-related mortality and prolonged hospitalization," David Palma, MD, MSc, lead author of the study and a radiation oncologist at the London Regional Cancer Program in London, Ontario, Canada, said. "All eligible patients should be evaluated in a multidisciplinary setting and afforded an informed decision of the risks and benefits of both surgery and SBRT."
###
ASTRO is the largest radiation oncology society in the world, with more than 10,000 members who specialize in treating patients with radiation therapies. As the leading organization in radiation oncology, biology and physics, the Society is dedicated to improving patient care through education, clinical practice, advancement of science and advocacy. For more information on radiation therapy, visit http://www.rtanswers.org. To learn more about ASTRO, visit http://www.astro.org.
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Source: http://www.eurekalert.org/pub_releases/2012-02/asfr-spb021612.php
mls superdraft school cancellations bald barbie peoples choice awards friends with kids andy cohen andy cohen
কোন মন্তব্য নেই:
একটি মন্তব্য পোস্ট করুন